{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T20:48:40Z","timestamp":1777927720436,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[1993,3,1]],"date-time":"1993-03-01T00:00:00Z","timestamp":730944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J STD AIDS"],"published-print":{"date-parts":[[1993,3]]},"abstract":"<jats:p>\n                    Pneumocystis carinii pneumonia (PCP) is the most frequent opportunistic infection in patients with AIDS, occurring in 80% and recurring in 50% of patients within 12 months of the first episode. Prophylaxis for PCP is recommended if the CD4+ cell count is &lt;200\u00d710\n                    <jats:sup>6<\/jats:sup>\n                    \/l or 20% of the total lymphocyte count, or after an episode of PCP. The most effective prophylactic agent currently is trimethoprim-sulphamethoxazole and should be the drug of choice but alternatives such as aerosol pentamidine are being increasingly used for patients who cannot tolerate this combination or other oral preparations. If aerosol pentamidine is used and administered via a Respigard II Marquest nebulizer, the dosage should be higher than the currently recommended monthly dosage of 300 mg.\n                  <\/jats:p>","DOI":"10.1177\/095646249300400202","type":"journal-article","created":{"date-parts":[[2017,1,15]],"date-time":"2017-01-15T16:02:45Z","timestamp":1484496165000},"page":"67-69","source":"Crossref","is-referenced-by-count":0,"title":["The Role of Aerosol Pentamidine Prophylaxis"],"prefix":"10.1177","volume":"4","author":[{"given":"E L C","family":"Ong","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Department of Medicine, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1993,3,1]]},"reference":[{"key":"bibr1-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706253162604"},{"key":"bibr2-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1001\/jama.259.8.1185"},{"key":"bibr3-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.1.254"},{"key":"bibr4-095646249300400202","unstructured":"Hardy WD, Wolfe PR, Gottlieb MS, Knight S, Mitsuyasu R, Young LS. Long-term follow-up of fansidar prophylaxis for\n                      Pneumocystis carinii\n                      in patients with AIDS. [Abstract TP 232]\n                      ***III International Conference on AIDs\n                      , Washington, DC, USA, 1987."},{"key":"bibr5-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199210000-00017"},{"key":"bibr6-095646249300400202","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-4-495"},{"key":"bibr7-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_2.S184"},{"key":"bibr8-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.31.7.978"},{"key":"bibr9-095646249300400202","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-4-495"},{"key":"bibr10-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91794-6"},{"key":"bibr11-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199009203231201"},{"key":"bibr12-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80080-6"},{"key":"bibr13-095646249300400202","unstructured":"Montaner JSG, Lawson L, Falutz J,  Aerosolized pentamidine for the secondary prophylaxis of\n                      Pneumocystis carinii\n                      pneumonia in the acquired immunodeficiency syndrome: a report from the Canadian cooperative trial [Abstract TBP54].\n                      V International Conference on AIDS\n                      , Montreal, Canada, 1989."},{"issue":"8","key":"bibr14-095646249300400202","first-page":"657","volume":"2","author":"Thomas S","year":"1989","journal-title":"Eur Resp J"},{"key":"bibr15-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92894-2"},{"key":"bibr16-095646249300400202","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/thx.45.4.304P","volume":"45","author":"Ong ELC","year":"1990","journal-title":"Thorax"},{"key":"bibr17-095646249300400202","first-page":"619","volume":"291","author":"Smith DE","year":"1991","journal-title":"Q J Med"},{"key":"bibr18-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1007\/BF01704600"},{"key":"bibr19-095646249300400202","doi-asserted-by":"crossref","unstructured":"Hardy WD, Holzman RS, Feinberg J,  Trimethoprim-sulfamethoxazole vs. aerolized pentamidine for secondary prophylaxis of\n                      Pneumocystis carinii\n                      pneumonia in AIDS patients: a prospective, randomized, controlled clinical trial (ACTG 021).\n                      Third European Conference on Clinical Aspects and Treatment of HIV Infection\n                      , Paris, France, 1992.","DOI":"10.1056\/NEJM199212243272604"},{"key":"bibr20-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03470060082031"},{"issue":"4","key":"bibr21-095646249300400202","first-page":"1","volume":"41","author":"Centers for Disease Control","year":"1992","journal-title":"MMWR"},{"key":"bibr22-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)93402-U"},{"key":"bibr23-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199202000-00004"},{"key":"bibr24-095646249300400202","unstructured":"Marc T Saint, Livrozet JM, Moreau J, Gamier JL, Sellem C, Touraine JL. Safety and efficacy of pyrimethamine-sulfadoxine in primary and secondary prophylaxis of pneumocystosis [Abstract WB2242].\n                      VII International Conference on AIDS\n                      , Florence, Italy, 1991."},{"key":"bibr25-095646249300400202","unstructured":"Fallon J, Hughes W, Lancaster D,  566C80 for the treatment of Pneumocystis pneumonia in AIDS [Abstract WB2239].\n                      VII International Conference on AIDS\n                      , Florence, Italy, 1991."},{"key":"bibr26-095646249300400202","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199211000-00015"}],"container-title":["International Journal of STD &amp; AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/095646249300400202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/095646249300400202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:50:24Z","timestamp":1777675824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/095646249300400202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,3]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,3]]}},"alternative-id":["10.1177\/095646249300400202"],"URL":"https:\/\/doi.org\/10.1177\/095646249300400202","relation":{},"ISSN":["0956-4624","1758-1052"],"issn-type":[{"value":"0956-4624","type":"print"},{"value":"1758-1052","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,3]]}}}